

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: BRUZZESE, T. Confirmation No.: 1570

Appln No.: 10/586,863 Examiner: KIM, J.M.

Filing Date: July 21, 2006 Group Art Unit: 1628

RE: USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED n-3  
FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM  
DISTURBANCES

DECLARATION UNDER 37 C.F.R. §1.132

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I, Dr. Tiberio Bruzzese, declare as follows:

1. I am the sole inventor in patent application 10/586,863 entitled " USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED n-3 FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES." I am currently President of the company Bixio Consulting S.r.l. located in Milano (Italy), via Bixio 30, and hold the professional title of Managing Director.

2. I hold a Degree in Industrial Chemistry from the University of Milano ( I ) and a Degree in Pharmacy from the University of Pavia ( I ) as described in more detail in a summary curriculum vitae (c.v.) appended hereto. Since 1960, I have worked regularly in the pharmaceutical field, including Pharmaceutical Chemistry, Pharmacology & Toxicology and Clinical Medicine. I have authored and co-authored about one hundred Publications or Congress Presentations regarding the same and I am an inventor or co-inventor of more than eighty Patents, as described in more detail in my summary c.v. appended hereto.

3. I have reviewed the Office Action dated May 25, 2010, and the prior art references cited therein.

4. I have reviewed the following independent claim as amended in the Amendment filed herewith. This claim is copied below and appears in italics:

*Claim 29 (Currently Amended): A method of using a composition, for the preparation of a drug for the prevention and/or treatment of the psychiatric disturbances of the central nervous system (CNS) selected from the group consisting of schizophrenia, manic-depressive syndrome, major depression, and Alzheimer's disease comprising a component selected from the group consisting of*

*a) alpha-linolenic acid (ALA, C18:3 n-3) and/or the pharmaceutically acceptable derivatives and/or precursors thereof;*

*b) docosahexaenoic acid (DHA, C22:6 n-3) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and*

*c) DHA in admixture with eicosapentaenoic acid (EPA, C20:5 n-3), in a ratio of 1:0.5 to 1: 1.7, respectively, and/or the pharmaceutically acceptable derivatives and/or precursors thereof;*

*wherein said component is present in a concentration not lower than 70% by weight of the total fatty acids weight in the composition;*

*with the provisos that:*

*when the composition comprises b), arachidonic acid is not added thereto; and*

*when the composition comprises c), it does not comprise 10 to 40% by weight of reducing/antioxidant vitamins or provitamins.*

5. Nishikawa et al. (U.S. Patent No. 6,306,907), Horrobin (U.S. Patent No. 4,977,187), and Chen (U.S. Patent No. 6,759,435) were determined by the examiner to render the claimed invention obvious. According to the examiner:

“The claims differ from the cited references in claiming combination of DHA and EPA and GLA composition of Horrobin to treat schizophrenia. To employ combinations of DHA and EPA & GLA (gamma-linolenic acid: n-6 essential fatty acid) composition to treat schizophrenia would have been obvious because all the components are well known individually for treating schizophrenia. It would be expected that the combination of components would treat schizophrenic conditions as well. One of ordinary skill in the art would have combined the antischizophrenic agents by known methods and that in combination, each element merely

would have performed the same antischizophrenic activity as it did separately.”

I respectfully disagree with these determinations for the reasons explained below.

6. Based on the conventional wisdom (including the teachings of the prior art) at the time the invention was made, the results of the claimed invention were unexpected. My experimental results described in Example 6 of the application, and in the subsequently-generated data described below, show that the presently claimed method alleviates symptoms of Schizophrenia in mammals. These results are unexpected, since the prior art teaches away from the claimed combination of DHA and EPA, and because the prior art teaches that GLA is an essential feature of a composition for treating Schizophrenia, yet the presently claimed method that alleviates Schizophrenia symptoms in mammals involves a composition that does not include GLA.

7. Subsequent to the filing of the present application, I generated additional data further demonstrating the efficacy of the presently claimed method for treatment of Schizophrenia. The additional experimentation showed, in a mouse model of induced schizophreniform psychosis, that pretreating mice with the presently claimed composition (Table 1 below) 4 weeks prior to inducing the schizophreniform psychosis resulted in attenuation of the schizophreniform psychosis (Table 2 below).

Table 1 - Materials

COMPOSITION	REMARKS ON FATTY ACIDS (assays by wt%)
BB <sup>1</sup>	EPA+DHA ethyl esters = 86.3 (48.2 + 38.1, respectively)
FF <sup>1</sup>	EPA+DHA ethyl esters = 89.5 (4.3 + 85.2, respectively)
Mellor et al. (MaxEPA®) <sup>2</sup>	EPA+DHA (glycerides) = 28.5 (17.1 + 11.4, respectively)
US 6,331,568/US 6,384,077 <sup>3</sup>	EPA+DHA ethyl esters = 95.3 (92.5 + 2.8, respectively) (other omega-6 = 2.6%)

<sup>1</sup>The compositions, BB and FF were prepared according to the disclosure of Example I of the present application as filed and fall within the definitions of the

compositions B and F of said example, respectively (see the table of page 8 of the present application).

<sup>2</sup>MaxEPA® is a dietary supplement commercialised by Seven Seas Healthcare Ltd, comprising, besides to EPA and DHA, substantial amounts of saturated, monounsaturated and omega-6 polyunsaturated components; it is used in Mellor J. et al.: "Omega-3 fatty acid supplementation in schizophrenic patients", Human Psychopharmacology, Clinical and experimental, John Wiley & Son, vol. II, no. I, 1996, pages 39-46 (e.g., page 40, left col., "Materials").

<sup>3</sup>EPA and DHA ethyl esters showing an assay falling within the disclosure of both US 6331568 - [f.i. col. 3, line 28 and col. 4, letters c) and d)] and US 6384077 - (f.i., col. 5, lines 59-60) were obtained from the distillate of the process leading to DHA ethyl ester (so-called D-1 product), according to W08911521 (mentioned for the preparation of Composition F, example I of the US application as filed, page 8, line 12). EPA ethyl ester from the distillate was further purified by silica gel chromatography (eluent: n-hexane) and by a final molecular distillation. Similar concentration/purification methods are summarized in US 6384077 (column 5, line 51 to column 6, line 3), which however does not disclose any specific experimental protocol.

Control groups were treated with olive oil. All compositions were administered in the volume of 5-10 ml/kg in mice. Positive control and experimental -groups were treated once with the reference substance, by ip route, diluted in saline solution.

## EXPERIMENTAL SECTION

Compositions BB and FF and MaxEPA® were screened in order to evaluate their ability to counteract the pathophysiology of schizophrenia; olive oil was used as a control.

The composition BB was also tested, following the teachings of the present application (see the specification of page 6, line 31 to page 7, line 26, specifically page 7, line 11), together with clozapine, another active principle suitable for the use of the invention in the treatment of schizophrenia.

Seven groups of 10 Swiss albino mice each were treated daily for 4 weeks, by oral route (gavage), according to the treatment scheme illustrated in the table below.

At the end of the treatment period, all the animals received by i.p. route 1 mg/Kg of dizocilpine (as described in the present specification, page 9, lines 14-18), an analogue of phencyclidine able to bind the N-methyl-D-aspartate (NMDA) receptors, inducing the hypofunction thereof and subsequent schizophreniform psychosis, resulting in irregular and intense jumping (so called "popping"). Popping attenuation represents a valid experimental model to screen substances able to counteract the pathophysiology of schizophrenia (Deutsch S. I. et al "Topiramate antagonizes MK-801 in an animal model of schizophrenia", Eu. J. of Pharmacology 449, pp. 121-125,2002, see page 121).

Following the administration of dizocilpine, the animals were monitored for 30 minutes and the popping behaviour, i.e. the number of jumps, was then registered.

Table 2

GROUP No.	COMPOSITION	DOSE (mg/kg)	RESULTS (No. of induced jumps)
1	BB	100	<b>43 ± 15</b>
2	BB	50	<b>66 ± 21</b>
3	BB + clozapine	25 + 25 i.p. (once)	<b>35 ± 8</b>
4	FF	50	<b>50 ± 6</b>
5	Mellor (MaxEPA®)	50	216 ± 35
6	Mellor (MaxEPA®)	200	194 ± 27
7	Control (olive oil)	-	292 ± 44

## RESULTS AND CONCLUSIONS

Both compositions BB and FF were able to attenuate a schizophreniform psychosis, in a dose-related manner and in combination with a sub-effective dose of clozapine -a known drug- as well. MaxEPA® resulted to be much less effective than compositions BB and FF.

Composition FF (comprising DHA substantially alone) resulted to be almost equipotent than composition BB whereas, according to US 6331568 and US 6384077, EPA should be considered as the effective compound, while DHA competes with EPA and is detrimental to its activity (see, for instance, US 6,331,568, col. 2, lines 30-58).

8. In addition, the prior art and conventional wisdom at the time the invention was made actually *teaches away* from the present claims. All the scientific works published after the publication of Nishikawa et al. in 1992 have led to the progressive acknowledgement that other omega-3 acids, particularly EPA, were definitely superior in activity with respect to DHA. For example and in particular, Mellor et al. (Human Psychopharm., 1996, listed on the IDS filed July 21, 2006), reported that omega-3 acids, especially EPA, improve the positive symptoms of schizophrenia and tardive dyskinesia, as demonstrated by the administration of fish oil (containing about 18% EPA and 12% DHA). Further, Mellor et al confirmed (see, e.g., the abstract, lines 1-2) that certain n-3 and n-6 EFAs are depleted in cell membranes from red blood cells (RBC) and brains of patients suffering from schizophrenia. It was also therein reported that a greater intake of n-3 fatty acids, especially EPA, was associated with less severe

schizophrenic symptoms, in particular positive symptoms, as well as tardive dyskinesia (TD, see, e.g., the abstract, lines 4-6). In fact, supplementation of the diet with 10g/day of concentrated fish oil (i.e. 18% of EPA and 12% of DHA, see Mellor et al., page 40, "Materials") was reported to result in significant amelioration of both schizophrenic symptoms and TD ascribable to the increased level of n-3 fatty acids in RBC membranes (abstract, lines 7-10 and page 41, paragraph bridging the columns). Table 5 of Mellor et al. shows a 274% EPA (20:5 n-3) increase (0.91 to 3.4 mg%) and a 41.8% DHA (22:6 n-3) increase (5.05 to 7.16 mg).

As another example, U.S. Patent No. 6,331,568 to Horrobin (the "568 patent", listed in the IDS filed July 21, 2006), describes the poor activity found in Mellor et al. and demonstrates that the actual active substances, rather than DHA, are EPA and SA (stearidonic acid), because both of them are efficient inhibitors of phospholipase PLA2, while DHA is not. In addition, the '568 patent remarks that the modestly beneficial effects obtained by supplementing a mixture of 18% EPA-12% DHA, as disclosed in Mellor et al., could have been caused by either component or both of them (col. I, line 64 to col. 2, line 3). In order to better understand the activity of n-3 fatty acids, the '568 patent therefore explores treating schizophrenia and TD by administering (col. 2, lines 8-20):

**('EPA group')** 20 ml of a 40% emulsion providing 8g of an oil containing 2.0 g (25%) of EPA and 0.4 g (5%) of DHA  
or

**('DHA group')** 20 ml of a 40% emulsion providing 8g of an oil containing 2.3g (28.75%) of DHA and 0.5g (6.25%) of EPA  
or

**placebo,**  
finding that "the DHA group was not significantly different from placebo, whereas the EPA group was significantly better than both the DHA group and the placebo group" (emphasis added, col. 2, lines 30 - 33). In particular, the author concludes that "there can be no doubt that EPA is primarily responsible for the positive effects" (col 2, lines 37-39), as it is further demonstrated, besides by clinical evidence, also by biochemical arguments, according to which **EPA is a potent inhibitor of phospholipase PLA2**,

**"whereas the relatively similar fatty acid, DHA is not"** (emphasis added, col. 2, lines 48-58).

Further, the '568 patent also discloses that another n-3 fatty acid, SA, "is as effective, in inhibiting PLA2, as is EPA" and that, **unlike DHA**, it can be advantageously effective in treating schizophrenia (col. 2, line 59 to col. 3, line 4). In other words, the '568 patent *teaches away* from the use of DHA and from the disclosure of Mellor et al. (see col. 1, lines 45-51) as to the significance and effectiveness of combining n-6 and n-3 fatty acids, i.e., *teaches away* from the combination of DHA and EPA, **shifting indeed the attention of the person skilled in the art to EPA and SA (both n-3 acids)**, which are only optionally combined with n-6 EFAs (see, e.g., claim 1 of the '568 patent).

As another example, in U.S. Patent No. 6,384,077 to Peet (the "‘077 patent", listed on the IDS filed July 21, 2006), this reference confirms the hypotheses of Horrobin in the '568 patent about the activity of EPA, if this substance is substantially pure and substantially free of DHA (col. 1, lines 54-63). In particular, the person skilled in the art is taught to treat psychiatric disorders by using pure or nearly pure EPA and its derivatives (col. 3, lines 14-19) based on the observation that the common pathological basis for the major psychotic mental illnesses – i.e. schizophrenia, bipolar disorder and major depression- and for many neurodegenerative disorders as well, can be identified with the hyperactivity of phospholipase PLA2 (col. 3, lines 20-32 and col. 4, lines 8-18), following the teachings of the '568 patent also for this aspect. The teachings of the '077 patent confirm that such hyperactivity can be effectively inhibited by highly purified EPA and that other fatty acids, among which DHA, compete with EPA, i.e. other PUFAs are detrimental to the activity of EPA (col. 6, lines 23-31), as clinically shown by comparing two preparations (25% EPA + 8% DHA - 96% EPA + DHA <3%: col. 6, lines 38-55). The '077 patent, however, discloses that the activity of substantially pure EPA must be carried out "*in conjunction with a drug which acts primarily on neurotransmitter metabolism or receptors*" (see e.g. claim 1 of the '077 patent).

In summary, all the scientific works published after 1992 would have led the skilled person towards selecting EPA for treating psychiatric and degenerative disturbances of CNS by discouraging the use of other PUFAs and, in particular,

representing a substantially uniform consensus to *opposing* the use of DHA (as presently claimed).

9. In summary, it is clear that the prior art *teaches away* from using DHA alone, and to use instead EPA, but not in association with DHA. In the instant combination of references, one of ordinary skill in the art would find no motivation, implicit or explicit, to alter the methods of Nishikawa et al., based on Horrobin's disclosure that an n-6 acid is necessary in a composition for treating schizophrenia, and Chen's disclosure of different types of schizophrenia. In addition, the results of the presently claimed method were unexpected. In view of the prior art's *teaching away* and the conventional wisdom at the time the invention was made, and because the results of the presently claimed invention were unexpected in view of the prior art, the presently claimed invention is non-obvious and inventive over the prior art.

10. I further state that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with my knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

21 September 2010

Date


Tiberio Bruzzese

Dr. Tiberio Bruzzese

## Summary CURRICULUM VITAE

The undersigned **TIBERIO BRUZZESE** is an **ITALIAN** citizen, currently residing in **MILANO (ITALY)** – via FRUA 21 /6.

- I hold a Degree in **Industrial Chemistry** from the University of Milano ( I ) in 1960 and a Degree in **Pharmacy** from the University of Pavia ( I ) in 1982.
- Assistant Professor of **General and Organic Chemistry** at the Politechnic University of Milano in 1960.
- **Chemical Research Manager** at the Istituto De Angeli Farmaceutici S.p.a. of Milano (1960 to 1967).
- **Chemical Research Director** (1967), **Research Director** (1974), then **member of the Board and vice-President & CEO** (1993 to 2002) at SPA-Società Prodotti Antibiotici S.p.a. of Milano.
- **Member of the board** of the Company PRO.BIO.SINT S.p.a. of Varese ( I ) and of the Company Solchem S.p.a. of Cassino d'Alberi ( I ).
- **President & Managing Director** of the Company Bixio Consulting S.r.l. of Milano ( I ) (2003 to the present ).
- Formerly **Member of Italian and US Associations** (AFI, SISF, ACS, AAAS).
- **Author or co-author** of about one hundred Publications or Congress Presentations, and **inventor or co-inventor** of more than eighty Patents in the field of Pharmaceutical Chemistry, Pharmacology and Clinical Medicine.



## PUBLICATIONS:

1. BRUZZESE T., CASNATI G., PIOZZI F., VITA-FINZI P.  
Degradazioni ossidative delle catene alifatiche di sistemi ciclici.  
Rendiconti Classe Scienze Fisiche, Matematiche e Naturali - Vol.XXX, 55, 1961  
Accademia Nazionale dei Lincei - Roma 1961
2. CASADIO S., PALA G., BRUZZESE T., MARAZZI-UBERTI E.  
Acidi naftilacetici.  
Nota I - Sintesi e attività coleretica di acidi 1-naftilacetici  $\alpha$ -sostituiti.  
Il Farmaco, Ed.Sc., XVII, 10, 797, 1962
3. CASADIO S., PALA G., BRUZZESE T., MARAZZI-UBERTI E.  
Acidi naftilacetici.  
Nota II - Sintesi e attività coleretica di acidi 2-naftilacetici  $\alpha$ -sostituiti.  
Il Farmaco, Ed.Sc., XVII, 10, 810, 1962
4. CASADIO S., PALA G., BRUZZESE T.  
Naftilacetonitrili.  
Nota I - 1- e 2-naftilacetonitrili sostituiti in  $\alpha$  con radicali alchilici.  
Il Farmaco, Ed.Sc., XVII, 11, 871, 1962
5. MARAZZI-UBERTI E., CASADIO S., BRUZZESE T.  
Azione farmacologica del 2-carbamil-fenossiacetato di tetraidrofurile (fenamidofurile).  
Arch.It.Scienze Farmacol., Serie III, VoLXIII, (1), 3, 1963
6. PALA G., BRUZZESE T.  
Relazioni tra effetti di sostituente e dati spettroscopici.  
Nota I - Effetti di sostituenti alifatici e aromatici sulla v ( $C\equiv N$ ) dell'acetonitrile.  
Annali di Chimica, Vol.54, 349, 1964
7. PALA G., BRUZZESE T., MANTEGANI A.  
Naftilacetamidi.  
Nota I - 1-naftilacetamidi secondarie e terziarie sostituite o non sostituite in  $\alpha$  con radicali alchilici.  
Il Farmaco, Ed.Sc., XIX, 3, 235, 1964
8. PALA G., BRUZZESE T., MARAZZI-UBERTI E., COPPI G.  
Naftilacetamidi.  
Nota II - 1-naftilacetamidi terziarie sostituite in  $\alpha$  con radicali amminoalchilici.  
Il Farmaco, Ed.Sc., XIX, 9, 731, 1964
9. PALA G., BRUZZESE T., MARAZZI-UBERTI E., COPPI G.  
Naftilchetonici basici.  
Il Farmaco, Ed.Sc., XIX, 11, 933, 1964
10. MANTEGANI A., TURBA C., BRUZZESE T., ZUGNA E.  
Esteri basici di acidi naftilacetici.  
Nota II - Sintesi ed azione spasmolitica di esteri amminofeniletilici di acidi 1-naftilacetici  $\alpha$  -sostituiti.  
Il Farmaco, Ed.Sc., XX, 1, 36, 1965

11. BRUZZESE T., CRESCENZI E., MARAZZI-UBERTI E.  
Nuovi eteri di fenoli.  
Nota III - Sintesi e farmacologia di eteri  $\alpha$ -glicerici, e di alcuni relativi  $\gamma$ -carbammati, di composti fenolici a struttura eterogenea.  
Il Farmaco, Ed.Sc., XX, 3, 165, 1965
12. BRUZZESE T., CASADIO S., MARAZZI-UBERTI E., TURBA C.  
Synthesis and pharmacological screening of 3-aminoalkyl-sydnones.  
J.Pharm.Sci., 54, 7, 1041, 1965
13. BRUZZESE T., CASADIO S., COPPI G., MARAZZI-UBERTI E.  
Synthesis and pharmacological screening of aminoalkyl-hydrazines.  
J.Pharm.Sci., 54, 7, 1056, 1965
14. BRUZZESE T., CRESCENZI E.  
N-aminoalkyl-  $\alpha$ -aminoacids and their corresponding ethyl esters.  
J.Pharm.Sci., 55, 7, 737, 1966
15. CASADIO S., PALA G., CRESCENZI E., BRUZZESE T., MARAZZI-UBERTI E., COPPI G.  
Synthesis and pharmacological evaluation of  $\alpha$ ,  $\alpha$ -disubstituted derivatives of phenylacetonitrile and 1-naphthylacetonitrile.  
J.Med.Chem., 8, 589, 1965
16. CASADIO S., PALA G., BRUZZESE T., CRESCENZI E., MARAZZI-UBERTI E., COPPI G.  
Synthesis and pharmacological evaluation of  $\alpha$ ,  $\alpha$ -disubstituted derivatives of phenylacetamide and 1-naphthylacetamide.  
J.Med.Chem., 8, 594, 1965.
17. PALA G., CASADIO S., BRUZZESE T., CRESCENZI E., MARAZZI-UBERTI E. Structure-activity relationships in antiinflammatory and analgesic compounds chemically related to  $\alpha$ -isopropyl- $\alpha$ -(2-dimethylaminoethyl)- 1-naphthylacetamide.  
J.Med.Chem., 8, 698, 1965
18. BRUZZESE T., TURBA C.  
A new naphthylacetamide derivative.  
J.Med.Chem., 9, 264, 1966
19. PALA G., BRUZZESE T., MARAZZI-UBERTI E., COPPI G.  
Synthesis and pharmacological evaluation of  $\alpha$ -substituted 1-naphthylacetic acids.  
J. Med.Chem., 9, 603, 1966
20. CASADIO S., BRUZZESE T., PALA G., COPPI G., TURBA C.  
Hypoglycemic activity and pharmacological picture of 4-(1-naphthyl) butylamine derivatives.  
J.Med.Chem., 9, 707, 1966
21. PALA G., CASADIO S., BRUZZESE T., COPPI G.  
Structure-hypoglycemic activity relationships in 1-naphthylalkylamines.  
J.Med.Chem., 9, 786, 1966

22. PALA G., CRESCENZI E., BRUZZESE T.  
Terpene compounds as drugs. II. Terpenyl derivatives of barbituric acids and normeperidine.  
J.Med.Chem.10, 507, 1967
23. PALA G., BRUZZESE T., LUMACHI B.  
Terpene compounds as drugs. V. Terpenyl derivatives of salicylic acid.  
J.Med.Chem.,11I, 910, 1968
24. BIANCHI C., BRUZZESE T., CASADIO S., COPPI G., PALA G., SANNA G.P., TURBA C.  
Anti-arrhythmic properties of 1, 5-dimorpholino-3- (1 -naphthyl) -pentane DA 1686.  
Experientia, 23, 243, 1967
25. PALA G., MANTEGANI A., BRUZZESE T., SEKULES G.  
212. Terpen-Verbindungen als Arzneimittel, IX Die vier stereoisomeren Geranylester der Farnesylessigsäure.  
Helv.Chim.Acta,53, 7, 1827, 1970
26. CASADIO S., PALA G., BRUZZESE T., TURBA C., MARAZZI-UBERTI E.  
Synthesis and pharmacological evaluation of a-naphthylalkylamines.  
J.Med.Chem., 13., 418, 1970
27. BRUZZESE T., BINDA I., DI NARDO A., GHIELMETTI G., RIVA M.  
Partricin methyl ester, a semisynthetic polyene antibiotic.  
Experientia, 28 1515, 1972
28. BRUZZESE T., GOI A., RIVA M.  
Synthesis and laxative properties of 4,4'- (2-picolylidene)-bisphenylphosphoric acid.  
Arzn.Forsch., 22, 531, 1972
29. BRUZZESE T., GOI A., RIVA M.  
Laxative properties of esters of 4,4'-dihydroxydiphenyl-(2pyridyl)methane.  
Il Farmaco, Ed.Sc., XXVIII, 2, 121, 1973
30. BRUZZESE T., PELLEGRINI R.  
Studies on new laxative products. Preliminary clinical data.  
Il Farmaco, Ed.Sc., XXVIII, 12, 987, 1973
31. GOI A., BRUZZESE T., GHIELMETTI G., RIVA M.  
Synthesis and pharmacological properties of pyridinecarbonyl derivatives of 7-substituted theophyllines.  
Chimie Thérapeutique, VIII 6, 634, 1973
32. BRUZZESE T., BINDA I., GHIELMETTI G., NOTARIANNI A.F.  
Partricin, an antifungal and antiprotozoal polyene antibiotic.  
Il Farmaco, Ed.Sc., XXIX, 4, 331, 1974
33. BRUZZESE T., CAMBIERI M., RECUSANI F.  
Synthesis and biological properties of alkyl esters of polyene antibiotics.  
J. Pharm.Sci., 64. 3, 462 (1975)

34. BRUZZESE T., DELL'ACQUA E., BIANCHI C., GOI A., RACCHELLI L, RECUSANI F. A soluble mepartricin complex (SPA-S-222) of potential oral and parenteral utility in fungal and protozoal infections.  
Il Farmaco, Ed.Sc., XXXI, 4, 291, 1976
35. NERI G., CAMBIERI M., BRUZZESE T.  
Stabilità di un sale idrosolubile dell'acido acetilsalicilico.  
Boll.Chim.Farm., 115, 845, 1976
36. GHIELMETTI G., BRUZZESE T., BIANCHI C., RECUSANI F.  
Relationship between acute toxicity in mice and polymorphic forms of polyene antibiotics.  
J.Pharm.Sci., 65\_, 6, 905, 1976
37. BRUZZESE T., RACCHELLI L, LOMI R., ROGNONI S.  
Action of gastric and intestinal simulated juice on mepartricin stability in solid and solubilized form.  
Il Farmaco, Ed.Pr., XXXII, 8, 422, 1977
38. DE BERNARDI M., CAMBIERI M., BRUZZESE T., RUOZI P.  
Farmacocinetica della mepartricina sodiolaurilsolfato.  
Ter.Ant.Chemoter., 28, 12, 1978
39. GOI A., BRUZZESE T., NOTARIANNI A.F., RIVA M., RONCHINI A.  
Synthesis and pharmacological properties of 3-O-derivatives of 1,2,5,6- Di-O-isopropylidene- $\alpha$ -D-glucofuranose.  
Arzn.Forsch., 29 (II), 7, 986, 1979
40. BRUZZESE T., CAMBIERI M.  
Guanidinated derivatives of lysozyme.  
Boll. Chim.Farm., 119, 303, 1980
41. GIAGNONI G., BRUZZESE T., DELL'ACQUA E. et al  
Attività costipante e tossicità acuta di derivati alchilici quaternari della loperamide.  
Riv.It.Biol.Med., 3, 1, 1983
42. BRUZZESE T., CEDRO A., DELL'ACQUA E, DI NARDO A., GOI A.  
New long-acting 3-azinomethyl-rifamycins.  
Il Farmaco, Ed.Sc. XLI, 3, 196, 1986
43. BRUZZESE T., SIGNORINI M., CEDRO A., FANCIANO C.A.  
Synthesis of lysozyme peptides endowed with analgesic activity.  
Riv.It.Biol.Med., 2., 3-4, 95, 1987
44. STRIPPOLI V., BRUZZESE T., GALLI R., SIMONETTI N.  
The antibacterial activity of a new 3-azinomethyl-rifamycin.  
Il Farmaco, Ed.Sc., XLIII, 7-8, 619, 1988
45. BRUZZESE T., CEDRO A., FANCIANO C.A., BASIUCO L, ANGEU A., FERRARI F., PATRINI G., GIAGNONI G.  
Antinociceptive properties of lysozyme fragments.  
Boll.Chim.Farm., 128, 1, 33, 1989

46. BASILICO L, PECORA N., BRUZZESE T., PAROLARO D. and GIAGNONI G.  
Lysozyme peptides antagonize induced hyperalgesia in the Randall-Selitto test.  
Curr.Therap.Res., 46, 4, 1989
47. BRUZZESE T. GIAGNONI G. AND BASILICO L.  
Evaluation of an Analgesic Lysozyme Peptide and of a D-Tyr Isomer  
Riv. It. Biol. Med. 11, 5-8, 1991
48. STRIPPOLI V., SIMONETTI N., VILLA A., BRUZZESE T.  
Antimicrobial activity of SPA-S-753, a new derivative of Partricin A.  
Eur.Bull.Drug Res., 1, 3, 113, 1992
49. STRIPPOLI V., SIMONETTI N., D'AURIA F.D., BRUZZESE T.  
*In vivo* activity of SPA- S-753, a water soluble polyene antibiotic effective against *C. albicans*  
Europ.Bull.Drug.Res., 3, 2, 71, 1994
50. MUNT P.L., BRUZZESE T. AND ALGATE D.R.  
Analgesic Activity of the Lysozyme Peptide N-(N-L-Threonyl-L- $\alpha$ -aspartil)-L-tyrosine in the Monkey  
and the Dog  
Arzn.Forsch./Drug Res. 45 (II), 7, 805-809, 1995
51. BRUZZESE T., RIMAROLI C., BONABELLO A., FERRARI E., SIGNORINI M.  
Amide derivatives of partricin A with potent antifungal activity  
Eur. J. Med. Chem., 31, 965, 1996
52. HAMILTON-MILLER J.M.T., BRUZZESE T., NONIS A. AND SHAH S.  
Comparative anti-gonococcal activity of S-565, a new rifamycin  
Int. J. Antimicr. Agents 7, 247-250, 1996
53. STRIPPOLI V., D'AURIA F.D., SIMONETTI N., BASTI D., BRUZZESE T.  
*In vitro* and *in vivo* antifungal activity of the polyene derivative SPA-S-753 against encapsulated form  
of *Cryptococcus neoformans*.  
Infection, 25, 1, 27, 1997
54. BONABELLO A., BRUZZESE T.  
Antifungal activity of SPA-S-843, in comparison with amphotericin B and fluconazole, on murine  
experimental infections (abstract P-89).  
Abstracts Trends Invas. Fungal Infect. 4, Barcelona p. 137, 1997
55. RIMAROLI C., BRUZZESE T.  
*In vitro* activity of a new polyene, SPA-S-843, against yeasts.  
Antim. Ag. Chemoter., 42, 11, 3012, 1998
56. KELKAR M.S., SARAF A. P., BAKHLE D.S., NAZARE V., AJAY S., HEGDE S., LAL H.M.,  
COOVERJI N.D., BRUZZESE T.  
Pharmacokinetic profile of a new 3-azinomethyl-rifamycin (SPA-S-565) in volunteers compared with  
conventional Rifampicin  
Int. J. Clin. Pharm. Res. XVIII (3), 137-143, 1998

57. POTKAR C., GOVTAY N., GOKHALE P., KSHIRSAGAR N. A., AJAY S. COOVERJI N. D. AND BRUZZESE T.  
Phase I Pharmacokinetic study of a new 3-azinomethyl-rifamycin Derivative (Rifametane) as compared to Rifampicin  
Chemotherapy, 45, 147-153, 1999

58. GALMOZZI M.R., BRUZZESE T. et al.  
Pharmacokinetics of a new derivative of partricin A (SPA-S-753) in rodents.  
Chemotherapy, 46, 153, 2000

59. RIMAROLI C., BRUZZESE T.  
Overview of SPA-S-843 *in vitro* activity against filamentous fungi.  
Chemotherapy, 46, 28, 2000

60. STRIPPOLI V., D'AURIA F.D., SIMONETTI G., BRUZZESE T. AND SIMONETTI N.  
Anticandidal activity of SPA-S-843, a new polyenic drug.  
J. Antimicr. Chemoter., 45, 235, 2000

61. BRUZZESE T., RIMAROLI C., BONABELLO A. MOZZI G., AJAY S. AND COOVERJI N. D.  
Pharmacokinetics and Tissue Distribution of Rifametane, a new 3-azinomethyl-rifamycin Derivative, in several Animal Species.  
Arzneimittel-Forschung/Drug Research 50 (I), 1, 60-71 (2000)

62. BONABELLO A., GALMOZZI M.R. BRUZZESE T. AND ZARA G.P.  
Analgesic effect of Bisphosphonates in Mice  
Pain 91, 269-275 , 2001

63. BRUZZESE T., GALMOZZI M. R., BUFFA G., SALA P. AND BONABELLO A.  
Pharmacokinetics in rats of N-dimethylaminoacetyl-Partricin A 2-dimethylaminoethylamide diascorbase (SPK-843)  
Chemotherapy, 47, 77, 2001

64. BRUZZESE T., GALMOZZI M. R., FERRARI V. M., SALA P., BONABELLO A.  
Comparative pharmacokinetics of three preparations of the new antifungal SPK-843  
Chemotherapy, 47, 387, 2001

65. RE G., BANDINO P., ODORE R., VIGO D., BONABELLO A., RABINO S., CAPELLO F. AND BRUZZESE T.  
Effects Of Mepartricin On Estradiol And Testosterone Serum Levels And On Prostatic Estrogen, Androgen And Adrenergic Receptor Concentrations In Adult Rats  
Pharmacological Res. 44 (2), 141-147, 2001

66. BARONE D., PEROGLIO F., TOSO E. AND BRUZZESE T.  
Binding Of Mepartricin To Sex Hormones, A Key Factor Of Its Activity On Benign Prostatic Hyperplasia  
Arzn.Forsch./Drug Res. 51 (II), 984-990, 2001

67. GALMOZZI M.R., BUFFA G., ROSSI C., BRUZZESE T., ZARA G.P. BONABELLO A.  
Clodronate has a long-lasting analgesic action  
Pharmacology and Toxicology, 89 (Suppl. 1) 134, 2001

68. MOZZI G., BENELLI P., BRUZZESE T., GALMOZZI M. R., BONABELLO A.  
The use of lipid emulsion for the i.v. administration of a new water soluble polyene antibiotic.  
J. Antimicrob. Chemother., 49, 321, 2002
69. BONABELLO A., GALMOZZI M.R., BRUZZESE T., MUNTONI E., ZARA G.P.  
Analgesic, Anti-inflammatory and gastric-damaging effects of dexibuprofen in rodents.  
Anesthesia & Analgesia 97 402-408, 2003
70. BONABELLO A., GALMOZZI M.R., BRUZZESE T., CANAPARO R., ZARA G.P.  
Long Term Analgesic Effect of Clodronate in rodents  
BONE 33, 567-574, 2003

## CONGRESSES:

1. STRIPPOLI V., TRONCI M., BRUZZESE T., GALLI R., SIMONETTI N.  
Attività antibatterica di una 3-azinometil-rifamicina.  
XXI Congresso Nazionale Società Italiana Microbiologia, Roma 4-7 Dicember 1985
2. SIMONETTI N., BRUZZESE T., STRIPPOLI V.  
"in vitro" and "in vivo" antibacterial activity of SPA-S-565, a new rifamycin derivative.  
IX Intern.Congress of Infect. and Paras. Diseases, Monaco 20-26 July 1986
3. SIMONETTI N., BRUZZESE T., STRIPPOLI V.  
SPA-S-565: a new azinomethyl-rifamycin.  
8th Intern.Symposium on Future Trends in Chemotherapy, Tirrenia (Pisa) 28-30 March 1988
4. STRIPPOLI V., D'AURIA F.D., BRUZZESE T., SIMONETTI N.  
Study of the in vitro activity of a water soluble mepartricin derivative  
*1<sup>st</sup> FIMUA Congress*, November 26-28, 1992, Firenze (Italy)
5. STRIPPOLI V., D'AURIA F.D., SIMONETTI N., BRUZZESE T.  
Protective activity of the polyene antibiotic SPA-S-753 in experimental *C. albicans* infections  
*24<sup>th</sup> Congresso Società Italiana Microbiologia* – September 14 - 18, 1992, Genova (Italy)
6. STRIPPOLI V., D'AURIA F.D., SIMONETTI N., BRUZZESE T.  
The anticryptococcal activity of SPA-S-753, a polyene antibiotic derivative of Partricin A  
*2<sup>nd</sup> FIMUA Congress* November 10-12, 1994, Torino (Italy)
7. RIMAROLI C., BONABELLO A., BRUZZESE T.  
Antimycotic activity in vitro of a new polyene antibiotic SPA-S-753 in comparison with Amphotericin B  
*2<sup>nd</sup> FIMUA Congress* November 10-12, 1994, Torino (Italy)
8. BONABELLO A., BRUZZESE T.  
Therapeutic efficacy of SPA-S-753, in comparison with Amphotericin B, against murine candidiasis and aspergillosis  
*XXVII Congresso Nazionale Società Italiana Farmacologia* – September 25 - 29, 1994, Torino (Italy)
9. BONABELLO A., GALMOZZI M. R. – BUFFA G., BRUZZESE T.  
Pharmacokinetics in rodents of a new semisynthetic polyene antibiotic (SPA-S-753) for systemic use  
*XII International Congress of Pharmacology* – July 24-29, 1994, Montreal (Canada)
10. GALMOZZI M. R., BUFFA G., BONABELLO A., BRUZZESE T.  
Pharmacokinetics in rabbit, rat and mouse of a new semisynthetic polyene antibiotic (SPA-S-753) for systemic use  
*XXVII Congresso Nazionale Società Italiana Farmacologia* – September 25-29, 1994, Torino (Italy)
11. BONABELLO A., RIMAROLI C., GALMOZZI M. R., BRUZZESE T.  
Pharmacokinetic study of SPA-S-753 and AmB on rats after intravenous treatment  
*2<sup>nd</sup> FIMUA Congress* November 10-12, 1994, Torino (Italy)

12. GALMOZZI M. R., BUFFA G., BRUZZESE T., BONABELLO A.  
Urinary and biliary recovery of a new antimycotic compound, SPA-S-753, in rats  
*First European Congress of Pharmacology* – June 16-19, 1995, Milano (Italy)
13. BONABELLO A., GALMOZZI M. R., BUFFA G., BRUZZESE T.  
SPA-S-753 – Subacute toxicity studies in Marmoset monkey by i.v. route  
*3<sup>rd</sup> FIMUA Congress* – October 3-5, 1996, Acireale (Italy)
14. GULMINETTI R., CAVANNA C., RIMAROLI C., BRUZZESE T., MARONE P.  
In vitro antifungal activity of a new polyene derivative, SPA-S-753  
*Conference "Focus on Fungal Infections"* – March 6-8, 1996, New Orleans, Louisiana – USA
15. STRIPPOLI V., SIMONETTI N., SIMONETTI G., BRUZZESE T.  
Studio sull'attività antifungina di SPA-S-843 nuova molecola polienica dotata di notevole efficacia e cronostabilità  
*3<sup>rd</sup> FIMUA Congress* – October 3-5, 1996, Acireale (Italy)
16. GULMINETTI R., RIMAROLI C., BRUZZESE T., MARONE P.  
Valutazione dell'attività antifungina in vitro di un nuovo derivato polienico: SPA-S-753  
*XXV Congresso Nazionale Associazione Microbiologi Clinici Italiani* – October 8-11, 1996, Pesaro (Italy)
17. GULMINETTI R., RIMAROLI C., BRUZZESE T., MARONE P.  
Attività antifungina in vitro di un nuovo derivato polienico, SPA-S-753, su ceppi fungini filamentosi isolati da pazienti AIDS  
*X Convegno Nazionale AIDS e Sindromi correlate* – November 21-23, 1996, Milano (Italy)
18. STRIPPOLI V., D'AURIA F.D., SIMONETTI N.  
"In vitro" antifungal activity of the polyene derivative SPA-S-843 against *Aspergillus* spp  
*13<sup>th</sup> Congress Intern. Society Human and Animal Mycology* – February 1, 1997 Salsomaggiore Terme (Italy)
19. STRIPPOLI V., D'AURIA F.D., BRUZZESE T., SIMONETTI N.  
Attività antifungina del derivato polienico SPA-S-843 verso *Aspergillus* spp  
*5<sup>o</sup> Congresso Nazionale Microbiologia Medica Odontoiatrica e Clinica* – June 20-21, 1997, Genova (Italy)
20. BONABELLO A., GALMOZZI M. R., BUFFA G., BRUZZESE T.  
*Rat serum and tissue distribution of SPK-843, a new semisynthetic polyene antibiotic*  
*13<sup>th</sup> Int. Congress of Pharmacology* – July 26-31, 1998, Munich (Germany)
21. RIMAROLI C., BRUZZESE T.  
In vitro activity of SPA-S-843 against *Candida* spp  
*5<sup>th</sup> ASM Conference on Candida and Candidiasis* – March 1-4, 1999 – Charleston, South Carolina – USA
22. RIMAROLI C., BRUZZESE T.  
In vitro activity of SPA-S-843 against filamentous fungi  
*5<sup>th</sup> Congress of the ECMM* – June 3 - 6, 1999, Dresden (Germany)

23. RIMAROLI C., BRUZZESE T.

In vitro activity of a new polyene, SPA-S-843

*International Meeting on ACCP* – October 27-30, 1999 – Santa Margherita Ligure – Portofino (Genova ) Italy

24. HEUER H. J., VAGADY M., MICHAEL-HEPP J., PABST G., BRUZZESE T.

Safety, Tolerability and Pharmacokinetic study with SPK-843, a new systemic antimycotic, by drip infusion in healthy volunteers

*AGAH Annual Meeting*, Feb. 19 – 21, 2006, Düsseldorf (Germany)

**RESULT LIST**

85 results found in the Worldwide database for:

Tiberio Bruzzese as the inventor

Sorting criteria:  Upload Date  Priority Date  Inventor  Applicant  Eca**1 PYRIDINECARBONYL DERIVATIVES OF 7-(.omega.-{(N-ALKYL-N-OPTIONALLY HYDROXYALKYL SUBSTITUTED****AMINO)-HYDROXYALKYL)-THEOPHYLLINE**

Inventor: BRUZZESE TIBERIO ; GHIelmetti Applicant: PRODOTTI ANTIBIOTICI SPA

GIUSEPPE

EC:

IPC:

Publication CA878502 (A) - 1971-08-17

Priority Date:

Info:

**2 SALTS OF PENICILLINS**

Inventor: BRUZZESE TIBERIO ; GHIelmetti

Applicant: PRODOTTI ANTIBIOTICI SPA [IT]

GIUSEPPE (+1)

EC: A61K31/43, C07D499/00

IPC: A61K31/43; C07D499/00; C07D499/22; (+2)

Publication GB1224235 (A) - 1971-03-03

Priority Date: 1968-07-23

Info:

**3 BASIC DERIVATIVES OF LYSOZYME**

Inventor: BRUZZESE TIBERIO ; GHIelmetti

Applicant: PRODOTTI ANTIBIOTICI SPA [IT]

GIUSEPPE (+1)

EC: C12N9/36

IPC: C12N9/36; C12N9/36

Publication GB1209214 (A) - 1970-10-21

Priority Date: 1968-07-23

Info:

**4 PYRIDINECARBONYL DERIVATIVES OF 7-(.OMEGA-{(N-ALKYL-N-OPTIONALLY HYDROXYALKYL SUBSTITUTED****AMINO)-HYDROXYALKYL)-THEOPHYLLINE**

Inventor: GHIelmetti GIUSEPPE ; BRUZZESE Applicant: PRODOTTI ANTIBIOTICI SPA

TIBERIO

EC: C07D473/08

IPC: C07D473/08; C07D473/00; (IPC1-

7): C07D57/48

Priority Date: 1968-12-10

Info:

**5 ESTERS OF DIPHENOLIC SUBSTANCES**

Inventor: BRUZZESE TIBERIO ; GHIelmetti

Applicant: PRODOTTI ANTIBIOTICI SPA [IT]

GIUSEPPE (+1)

EC: C07D209/34; C07D213/30; (+5)

IPC: C07D209/34; C07D213/30; C07F9/12; (+7)

Publication GB1292472 (A) - 1972-10-11

Priority Date: 1970-06-16

Info:

**6 BASIC DERIVATIVES OF LYSOZYME**

Inventor: BRUZZESE TIBERIO ; GHIelmetti

Applicant: PRODOTTI ANTIBIOTICI SPA

GIUSEPPE (+1)

EC: C12N9/36

IPC: C12N9/36; C12N9/36; (IPC1-7): A61K19/00

Publication US3859435 (A) - 1975-01-07

Priority Date: 1968-04-21

Info:

**7 Analogifremgangsmåde til fremstilling af 4,4'-disulfoxy-diphenyl-(2-pyridyl)-methanderivater.**

Inventor: BRUZZESE TIBERIO [IT]

Applicant: PRODOTTI ANTIBIOTICI SPA [IT]

EC: C07D213/30

IPC: C07D213/30; C07D213/00; (IPC1-

7): C07D213/30

Priority Date: 1971-09-17

Publication DK138986 (B) - 1978-11-27

Info: DK138986 (C) - 1979-05-07

**8 4-ACETOXY-4-(40 -SULFOXYDIPHENYL-(2-PYRIDYL)****METHANE AND SODIUM SALT THEREOF**

Inventor: BRUZZESE TIBERIO ; GHIelmetti

Applicant: PRODOTTI ANTIBIOTICI SPA

GIUSEPPE (+1)

EC: C07D209/34; C07F9/12; (+3)

IPC: C07D209/34; C07F9/12; C07F9/40; (+5)

Publication US3873551 (A) - 1975-03-25

Priority Date: 1970-06-16

Info:

**9 3,3-BIS-(P-PHOSPHONOXY- AND P-SULPHOXY-PHENYL)-2-INDOLINONES**

Inventor: BRUZZESE TIBERIO ; GHIelmetti

Applicant: PRODOTTI ANTIBIOTICI SPA

GIUSEPPE (+1)

EC: C07D209/34; C07F9/12; (+1)

IPC: C07D209/34; C07F9/12; C07F9/58; (+3)

Publication US3901912 (A) - 1975-08-26

Priority Date: 1970-06-16

Info:

**10 Alkyl esters of polyene antibiotics**

Inventor: BRUZZESE TIBERIO ; FERRARI

Applicant: PRODOTTI ANTIBIOTICI SPA

RODOLFO

EC: C07H17/08

IPC: A61K35/74; A61P31/00; C07G11/00; (+6)

Publication US3936528 (A) - 1976-02-03

Priority Date: 1972-07-24

Info:

**11 Process for preparing 4,4-disulphoxy-diphenyl-(2-pyridyl)-methane derivatives**

Inventor: BRUZZESE TIBERIO

Applicant: PRODOTTI ANTIBIOTICS S P A SPA

EC:

IPC: (IPC1-7): C07D31/48

Publication US3882131 (A) - 1975-05-06

Priority Date: 1971-09-17

Info:

**12 ESTERS OF PARTRICIN AND OF PARTRICIN DERIVATIVES**

Inventor: BRUZZESE TIBERIO ; GHIelmetti

Applicant: PRODOTTI ANTIBIOTICI SPA

GIUSEPPE

EC: C07H17/08G

IPC: A61K35/74; A61P31/00; A61P31/04; (+10)

Publication CA1025848 (A1) - 1978-02-07

Priority Date: 1973-02-15

Info:

WERKWIJZE VOOR HET BEREIDEN VAN EEN AL DAN NIET

**GEVORMD FARMACEUTISCH PREPARAAT EN WERKWIJZE  
13 VOOR HET BEREIDEN VAN HET WERKZAME BESTANDDEEL  
DAARIN.**  
Inventor: BRUZZESE TIBERIO ; FERRARI RODOLFO  
EC: C07D213/30; C07D213/55; (+1)  
Publication CH603583 (A5) - 1978-08-31  
Info:  
**Process for preparing dihydroxydiphenylmethane derivatives**  
Inventor: BRUZZESE TIBERIO ; FERRARI RODOLFO  
EC: C09B11/26  
Publication US3963732 (A) - 1976-06-15  
Info:  
**SALZE UND KOMPLEXE VON LYSOZYM UND  
15 LYSOZYMDERIVATE**  
Inventor: BRUZZESE TIBERIO [IT]; FERRARI RUDOLFO [IT]  
EC: C12N9/36  
Publication DE2457107 (A1) - 1975-06-12  
Info:

Data supplied from the **espacenet** database — Worldwide

**RESULT LIST**

85 results found in the Worldwide database for:

**Tiberio Bruzze** as the inventorSorting criteria:  **Upload Date**  Priority Date  Inventor  Applicant  Ecla**16 ALKYL ESTERS OF POLYENE ANTIBIOTICS**

**Inventor:** BRUZZESE TIBERIO ; FERRARI RODOLFO  
**EC:** C07H17/08  
**Publication** US4038382 (A) - 1977-07-26  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA  
**IPC:** C07H17/08; C07H17/00  
**Priority Date:** 1972-07-24

**17 LYSOZYME DERIVATIVES**

**Inventor:** BRUZZESE TIBERIO ; FERRARI RODOLFO  
**EC:** A61K38/47; C07J9/00B  
**Publication** US3937815 (A) - 1976-02-10  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA  
**IPC:** A61K38/47; C07J9/00; A61K38/43; (+3)  
**Priority Date:** 1975-12-05

**18 VERFAHREN ZUR HERSTELLUNG VON**

**ISOBUTYLPHENYLVERBINDUNGEN**

**Inventor:** BRUZZESE TIBERIO [IT] ; CAMBIERI MAURIZIO [IT] (+1)  
**EC:** C07C51/09  
**Publication** DE2614306 (A1) - 1976-10-21  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA  
**IPC:** B01J23/00; B01J27/00; C07B61/00; (+17)  
**Priority Date:** 1975-04-03

**19 Process for the preparation of isobutylphenyl compounds**

**Inventor:** BRUZZESE TIBERIO [IT] ; CAMBIERI MAURIZIO [IT] (+1)  
**EC:** C07C51/16; C07C51/16  
**Publication** CH624086 (A5) - 1981-07-15  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** C07C51/16; C07C51/16; (IPC1-7); C07C57/30  
**Priority Date:** 1976-05-21

**20 Method for the treatment of dyslipidaemia and arteriosclerosis**

**Inventor:** BRUZZESE TIBERIO [IT] ; FERRARI LORENZO [IT]  
**EC:** A61K31/70  
**Publication** US4192864 (A) - 1980-03-11  
**Info:**

**Applicant:** PROSPA NV [NL]  
**IPC:** A61K31/00; A61K35/00; A61K31/00; (+2)  
**Priority Date:** 1977-05-30

**21 A NEW POLYENIC ANTIBIOTIC**

**Inventor:** TIBERIO BRUZZESE ; RODOCFO FERRARI  
**EC:** A61K31/70; C07H17/08  
**Publication** MY20578 (A) - 1978-12-31  
**Info:**

**Applicant:** SPA SOCIETA PRODOTTI ANTIBIOTICI  
**IPC:** C07H17/08; C07H17/00; (IPC1-7); A61K31/71; (+1)  
**Priority Date:** 1970-11-03

**22 Method of relieving pain and treating inflammatory conditions in warm-blooded animals**

**Inventor:** BRUZZESE TIBERIO ; FERRARI RODOLFO  
**EC:** C07C57/30; C07C57/46; (+3)  
**Publication** US4279926 (A) - 1981-07-21  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA  
**IPC:** A61K31/205; A61P29/00; C07C227/18; (+27)  
**Priority Date:** 1974-03-07

**23 Glucofuranose derivatives**

**Inventor:** BRUZZESE TIBERIO ; FERRARI LORENZO (+1)  
**EC:** C07H15/04C  
**Publication** US4251520 (A) - 1981-02-17  
**Info:**

**Applicant:** BRUZZESE TIBERIO ; FERRARI LORENZO (+1)  
**IPC:** A61K31/70; A61P29/00; C07H15/04; (+7)  
**Priority Date:** 1976-11-16

**24 Method for the treatment of benign prostatic hypertrophy**

**Inventor:** BRUZZESE TIBERIO ; FERRARI LORENZO  
**EC:** A61K31/70  
**Publication** US4237117 (A) - 1980-12-02  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA  
**IPC:** A61K35/00; A61K35/00; (IPC1-7); A61K35/00  
**Priority Date:** 1979-10-05

**25 ACIDI IDROSSAMICI SOSTITUITI,PROCEDIMENTO PER LA LORO PREPARAZIONE E COMPOSIZIONI FARMACEUTICHE CONTENENTI Detti ACIDI**

**Inventor:** BRUZZESE TIBERIO [IT] ; DELL ACQUA ERNANI [IT] (+1)  
**EC:**  
**Publication** IT1130557 (B) - 1986-06-18  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** C07C; (IPC1-7); C07C  
**Priority Date:** 1980-03-18

**26 DERIVATI DIFENILALCANI SOSTITUITI,PROCEDIMENTO PER LA LORO PREPARAZIONE E LORO IMPIEGO FARMACEUTICO**

**Inventor:** BRUZZESE TIBERIO [IT] ; DELL ACQUA ERNANI [IT] (+1)  
**EC:**  
**Publication** IT1131136 (B) - 1986-06-18  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** A61K; (IPC1-7); A61K  
**Priority Date:** 1980-05-02

**27 Derivatives of rifamycins, their preparation and pharmaceutical compositions thereof**

**Inventor:** BRUZZESE TIBERIO [IT] ; FERRARI LORENZO [IT]  
**EC:** C07D498/22  
**Publication** US4372961 (A) - 1983-02-08  
**Info:**

**Applicant:** BRUZZESE TIBERIO [IT] ; FERRARI LORENZO [IT]  
**IPC:** A61K31/435; A61P31/04; C07D498/22; (+5)  
**Priority Date:** 1980-07-18

## Info:

**28 PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 1,3-OXAZINO-(5,6,-C) RIFAMYCINS**  
Inventor: BRUZZESE TIBERIO      Applicant: HOLCO INVESTMENT INC  
EC: C07D498/08; C07D498/18      IPC: A61K31/535; A61P31/04; C07D498/08; (+6)  
Publication IN151954 (A1) - 1983-09-10      Priority Date: 1977-11-25  
Info:

**29 Anti-inflammatory 1,2-benzothiazines**  
Inventor: DELL ACQUA ERNANI [IT]; BRUZZESE TIBERIO [IT] (+1)      Applicant: PRODOTTI ANTIBIOTICI SPA [IT]  
EC: C07D417/12      IPC: A61K31/54; A61P25/04; A61P29/00; (+7)  
Publication US4461768 (A) - 1984-07-24      Priority Date: 1981-11-12  
Info:

**30 RIFAMYCINDERIVATE, HERSTELLUNG UND DIESE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN.**  
Inventor: BRUZZESE TIBERIO; DELL ACQUA ERNANI (+1)      Applicant: PRODOTTI ANTIBIOTICI SPA [IT]  
EC:      IPC: A61K31/395; C07D498/08; A61K31/395; (+3)  
Publication AT23719 (T) - 1986-12-15      Priority Date: 1983-03-24  
Info:

Data supplied from the **espacenet** database — Worldwide

**RESULT LIST**

85 results found in the Worldwide database for:

Tiberio Bruzze

Sorting criteria:  **Upload Date**  Priority Date  Inventor  Applicant  Ecl4**31 Rifamycins derivatives and preparation and pharmaceutical compositions thereof**

**Inventor:** BRUZZESE TIBERIO [IT]; DELL ACQUA ERNANI [IT] (+1)  
**EC:** C07D498/08  
**Publication:** US4562203 (A) - 1985-12-31  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** A61K31/395; A61K31/445; A61K31/535;  
**(+10)**  
**Priority Date:** 1983-03-24

**32 VERFAHREN ZUR HERSTELLUNG VON BENZOTHIAZINVERBINDUNGEN.**

**Inventor:** BRUZZESE TIBERIO ; DELL ACQUA ERNANI (+2)  
**EC:**  
**Publication:** AT41000 (T) - 1989-03-15  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** C07D279/02; C07D417/12; C07D275/06;  
**(+6)**  
**Priority Date:** 1983-12-16

**33 Process for preparing 2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide derivatives and intermediates therefor**

**Inventor:** BRUZZESE TIBERIO [IT]; DELL ACQUA ERNANI [IT] (+2)  
**EC:** C07D279/02; C07D417/12  
**Publication:** US4599406 (A) - 1986-07-08  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** C07D279/02; C07D417/12; C07D279/00;  
**(+2)**  
**Priority Date:** 1983-12-16

**34 PANTOTHENOL DERIVATIVES.**

**Inventor:** BRUZZESE TIBERIO ; OTTONI FRANCO (+1)  
**EC:**  
**Publication:** AT54307 (T) - 1990-07-15  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** A61K31/22; C07C235/08; A61K31/21; (+3)  
**Priority Date:** 1985-10-08

**35 Pantethenyl derivatives**

**Inventor:** BRUZZESE TIBERIO [IT] ; OTTONI FRANCO [IT] (+1)  
**EC:** C07C229/12  
**Publication:** US4721728 (A) - 1988-01-26  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** A61K31/205; A61P43/00; C07C229/12; (+8)  
**Priority Date:** 1985-10-08

**36 Peptides correlated to lysozyme**

**Inventor:** BRUZZESE TIBERIO [IT] ; CEDRO ARMANDO [IT] (+1)  
**EC:** C12N9/36; C12P21/06  
**Publication:** US4784988 (A) - 1988-11-15  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** A61K38/43; A61K38/46; A61P25/04; (+28)  
**Priority Date:** 1985-12-11

**37 Process for obtaining foods free of Listeria bacteria**

**Inventor:** DELL ACQUA ERNANI [IT]; BRUZZESE TIBERIO [IT] (+1)  
**EC:** A23C19/04E; A23C9/12B6; (+2)  
**Publication:** US4810508 (A) - 1989-03-07  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** A23C13/08; A23C15/18; A23C19/04; (+19)  
**Priority Date:** 1986-10-28

**38 NOUVEAUX ANTAGONISTES DE L'ALDOSTERONE.**

**Inventor:** GHIELMETTI GIUSEPPE [IT]; BRUZZESE TIBERIO [IT] (+2)  
**EC:** C07J21/00B1; C07J31/00B  
**Publication:** BE1000952 (A3) - 1989-05-23  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA  
**IPC:** C07J21/00; C07J31/00; C07J21/00; (+3)  
**Priority Date:** 1986-12-17

**39 Rifamycin derivative salts**

**Inventor:** BRUZZESE TIBERIO [IT]; CEDRO ARMANDO [IT] (+1)  
**EC:** C07D498/08  
**Publication:** PT86621 (A) - 1988-02-01  
**Info:** PT86621 (B) - 1991-12-31

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** C07D498/08; C07D498/00; (IPC1-7); A61K31/33; (+1)  
**Priority Date:** 1987-01-26

**40 Anti-hypertensive compound with beta blocking and diuretic action**

**Inventor:** CECCHETTI VIOLETTA ; FRAVOLINI ARNALDO (+2)  
**EC:**  
**Publication:** IT1227160 (B) - 1991-03-20  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** A61K; (IPC1-7); A61K  
**Priority Date:** 1988-07-21

**41 VERFAHREN ZUR SYNTHESE EINES BENZO[*ij*]CHINOLIZIN-2-CARBONSÄURE-DERIVATES.**

**Inventor:** BRUZZESE TIBERIO ; SIGNORINI MASSIMO (+1)  
**EC:**  
**Publication:** AT86254 (T) - 1993-03-15  
**Info:**

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** C07D405/06; C07D455/04; C07D405/00; (+3)  
**Priority Date:** 1987-10-05

**42 Process for the synthesis of a benzo [ij] quinolizine-2-carboxylic acid derivative.**

**Inventor:** BRUZZESE TIBERIO ; SIGNORINI MASSIMO (+1)  
**EC:** C07D405/06; C07D455/04  
**Publication:** EP0310849 (A1) - 1989-04-12

**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** B01J31/02; C07B61/00; C07D405/06; (+7)  
**Priority Date:** 1987-10-05

Info: EP0310849 (B1) - 1993-03-03

**43 PHARMACOLOGICALLY ACTIVE PEPTIDE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM**

Inventor: BRUZZESE TIBERIO [IT]; SIGNORINI Applicant: PRODOTTI ANTIBIOTICI SPA [IT]  
MASSIMO [IT] (+2)  
EC: C07K5/08A1A; C07K5/08A1F IPC: A61K38/00; A61P25/04; A61P31/12; (+9)  
Publication US5182265 (A) - 1993-01-26 Priority Date: 1989-08-28  
Info:

**44 POLYENE MACROLIDE DERIVATIVES**

Inventor: BRUZZESE TIBERIO [IT]; OTTONI Applicant: PRODOTTI ANTIBIOTICI SPA [IT]  
FRANCO [IT] (+1)  
EC: C07H17/08G IPC: A61K31/70; A61K31/7042; A61K31/7048;  
(+8)  
Publication KR100185200 (B1) - 1999-05-15 Priority Date: 1989-11-16  
Info:

**45 A method for the production of complexes of long chain polyunsaturated fatty acids and their derivatives, with cyclodextrins, and the resulting complexes.**

Inventor: BRUZZESE TIBERIO [IT]; MOZZI Applicant: STAROIL LTD [IS]  
GIOVANNI [IT]  
EC: A61K47/48W18B; C08B37/00M2B2; (+1) IPC: A61K31/20; A61K31/202; A61K31/23; (+18)  
Publication PT98606 (A) - 1992-06-30 Priority Date: 1990-08-09  
Info: PT98606 (B) - 1999-01-29

Data supplied from the **espacenet** database — Worldwide

**RESULT LIST**

85 results found in the Worldwide database for:

Tiberio Bruzze

Sorting criteria:  **Upload Date**  Priority Date  Inventor  Applicant  Ecla**46 Particin derivatives**

**Inventor:** BRUZZESE TIBERIO [IT]; SIGNORINI **Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**MASSINO** [IT] (+1)  
**EC:** C07H17/08G **IPC:** A61K31/70; A61K31/7042; A61K31/7048;  
**(+18)**  
**Publication** US5298495 (A) - 1994-03-29 **Priority Date:** 1990-12-03  
**Info:**

**47 Particine derivatives, process for preparing them and pharmaceutical compositions containing them**

**Inventor:** SIGNORINI MASSIMO [IT]; OTTONI **Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**FRANCO** [IT] (+1)  
**EC:** **IPC:** A61K31/70; C07H17/08; A61K; (+5)  
**Publication** PT99964 (A) - 1993-07-30 **Priority Date:** 1992-01-02  
**Info:** PT99964 (B) - 1999-06-30

**48 PROCESSO PER LA SINTESI DELLA 2-AMMINO-6-CLOROPURINA**

**Inventor:** BRUZZESE TIBERIO; ROGNONI **Applicant:** SOLAR CHEMICALS S A [LU]  
**MARCO**  
**EC:** **IPC:** C07D; (IPC1-7): C07D  
**Publication** IT1264862 (B1) - 1996-10-17 **Priority Date:** 1993-06-21  
**Info:**

**49 Pharmaceutical compositions containing esters of omega-3 polyunsaturated acids and their use in the topical treatment of morbid affections.**

**Inventor:** BRUZZESE TIBERIO; MOZZI **Applicant:** PROSPA BV [NL]  
**GIOVANNI** [IT] (+1)  
**EC:** A61K31/20; A61K31/23; (+8) **IPC:** A61K31/20; A61K31/23; A61K47/10; (+18)  
**Publication** NO932843 (A) - 1994-02-14 **Priority Date:** 1992-08-11  
**Info:** NO309363 (B1) - 2001-01-22

**50 Process for the synthesis of 2-amino-6-chloropurine**

**Inventor:** BRUZZESE TIBERIO; ROGNONI **Applicant:** SOLAR CHEM SA [LU]  
**MARCO**  
**EC:** **IPC:** C07D401/00; C07D; C07D401/00; (+1)  
**Publication** IT1269881 (B) - 1997-04-15 **Priority Date:** 1994-06-02  
**Info:**

**51 Process for the synthesis of 9-(2-hydroxyethoxy methyl) guanine**

**Inventor:** BRUZZESE TIBERIO [IT]; GUAZZI **Applicant:** SOLAR CHEM SA [LU]  
**GIUSEPPE** [IT] (+2)  
**EC:** C07D473/00; C07D473/18 **IPC:** C07D473/00; C07D473/00;  
**(+1)**  
**Publication** US5496945 (A) - 1996-03-05 **Priority Date:** 1993-06-14  
**Info:**

**52 Pharmaceutical preparations containing polyunsaturated fatty acids, their esters or salts, together with antioxidant vitamins or provitamins**

**Inventor:** BRUZZESE TIBERIO [IT] **Applicant:** PROSPA BV [NL]  
**EC:** A61K31/375 **IPC:** A61K31/015; A61K31/07; A61K31/20; (+22)  
**Publication** US5776978 (A) - 1998-07-07 **Priority Date:** 1994-08-25  
**Info:**

**53 Salts of a polyunsaturated fatty acid and pharmaceutical formulations containing them**

**Inventor:** BRUZZESE TIBERIO [IT] **Applicant:** PROSPA BV [NL]  
**EC:** C07C229/26; C07C279/16; (+1) **IPC:** A61K31/195; A61K31/198; A61K31/20;  
**(+17)**  
**Publication** US5750572 (A) - 1998-05-12 **Priority Date:** 1993-12-14  
**Info:**

**54 PRODUCTION OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE**

**Inventor:** DE MEGLIO GIUSEPPE [IT]; ORDANINI GIANCARLO [IT] (+1) **Applicant:** PRO BIO SINT SRL [IT]  
**EC:** C07H19/06E **IPC:** A61K31/70; A61K31/7042; A61K31/7052;  
**(+15)**  
**Publication** JP9165396 (A) - 1997-06-24 **Priority Date:** 1995-08-03  
**Info:**

**55 COATED COMPOSITIONS CONTAINING POLYENE DERIVATIVES**

**Inventor:** BRUZZESE TIBERIO [IT]; MOZZI **Applicant:** PRODOTTI ANTIBIOTICI SPA [IT];  
**GIOVANNI** [IT] **BRUZZESE TIBERIO** [IT] (+1)  
**EC:** A61K9/28K **IPC:** A61K9/28; A61K9/32; A61K9/36; (+4)  
**Publication** WO9747311 (A1) - 1997-12-18 **Priority Date:** 1996-06-12  
**Info:**

**56 Salts of omega-3-polyunsaturated fatty acids and pharmaceutical formulations containing them**

**Inventor:** BRUZZESE TIBERIO [IT] **Applicant:** PROSPA BV [NL]  
**EC:** C07C215/08; C07C215/12; (+2) **IPC:** A61K31/205; A61P7/02; C07C215/08; (+9)  
**Publication** US5869714 (A) - 1999-02-09 **Priority Date:** 1994-10-20  
**Info:**

**57 Antitumoral method by administration of particin derivatives**

**Inventor:** BRUZZESE TIBERIO [IT] **Applicant:** PROSPA BV [NL]  
**EC:** A61K31/70; A61K31/706 **IPC:** A61K31/70; A61K31/70; (IPC1-7); A61K31/70  
**Publication** US5914321 (A) - 1999-06-22 **Priority Date:** 1997-09-19  
**Info:**

Info:  
**USO DI BISFOSFONATI PER LA PREPARAZIONE DI  
58 MEDICAMENTI SOMMINISTRABILI MEDIANTE  
IONTOFORSI**  
Inventor: BRUZZESE TIBERIO [IT]; MOZZI GIOVANNI (+1)  
EC: Publication IT1295941 (B1) - 1999-05-28  
Info:  
**Use of bisphosphonates in pharmaceutical preparations**  
**59 Intended for intramuscular use**  
Inventor: BRUZZESE TIBERIO [IT]; MOZZI GIOVANNI [IT] (+1)  
EC: A61K47/10; A61K9/00M5; (+1)  
Publication BE1012137 (A3) - 2000-05-02  
Info:  
**60 ANTITUMORAL METHOD BY ADMINISTRATION OF  
PARTRICIN DERIVATIVES**  
Inventor: BRUZZESE TIBERIO [IT]  
EC: A61K31/7048; A61K31/706  
Publication CA2255804 (A1) - 2000-06-07  
Info: CA2255804 (C) - 2009-07-28

Applicant: PRODOTTI ANTIBIOTICI SPA [IT]  
IPC: A61K; (IPC1-7): A61K  
Priority Date: 1997-11-05

Applicant: PRODOTTI ANTIBIOTICI SPA [IT]  
IPC: A61K31/66; A61K47/10; A61K9/00; (+5)  
Priority Date: 1997-11-21

Applicant: PROSPA BV [NL]  
IPC: (IPC1-7): A61K31/71  
Priority Date: 1998-12-07

---

Data supplied from the **espacenet** database — Worldwide

**RESULT LIST**

85 results found in the Worldwide database for:

**Tiberio Bruzzone as the inventor**Sorting criteria: **Upload Date** Priority Date Inventor Applicant Ecls**SUPPRESSION OF TUMOR BY ADMINISTRATION OF****61 PARTRICIN DERIVATIVE****Inventor:** BRUZZESE TIBERIO**Applicant:** KUATEKKUSU NV**EC:****IPC:** A61K31/00; A61K31/28; A61K31/282; (+38)**Publication** JP2000169377 (A) - 2000-06-20**Priority Date:** 1998-12-08**Info:****Partricinderivate zur prophylaktischen und/oder heilenden****62 Behandlung von Pilzkontamination in Zell- und Gewebekulturen****Inventor:** BRUZZESE TIBERIO [IT]**Applicant:** PRO APARTS INVESTIMENTOS E CON [PT]**EC:****IPC:** A01N1/02; A61K31/70; A61L2/00; (+12)**Publication** DE69829190 (T2) - 2005-07-21**Priority Date:** 1998-12-10**Info:****Partricin derivatives in the prophylactic and/or curative****63 treatment of fungal contamination of cell cultures and of tissues****Inventor:** BRUZZESE TIBERIO [IT]**Applicant:** QUATEX NV [AN]**EC:** A61K31/70**IPC:** A61K31/70; A61K31/70; (IPC1-7); A01N1/02; (+4)**Publication** EP1013289 (A1) - 2000-06-28**Priority Date:** 1997-09-16**Info:** EP1013289 (B1) - 2005-03-02**Complexes of N'-dimethylaminoacetylpartricin A****64 dimethylaminoethylamide, or the salts thereof, and cholesterol 3-sulphate****Inventor:** BRUZZESE TIBERIO [IT]; MOZZI GIOVANNI [IT]**Applicant:** QUATEX NV [NL]**EC:** A61K47/48H4; A61K47/48H4N; (+2)**IPC:** A61K31/575; A61K31/70; A61K47/48; (+4)**Publication** US6143726 (A) - 2000-11-07**Priority Date:** 1996-07-12**Info:****65 Antitumoral method by administration of partricin derivatives****Inventor:** BRUZZESE TIBERIO [IT]**Applicant:** PROSPA BV [NL]**EC:** A61K31/7048; A61K31/706**IPC:** A61K31/505; A61K31/70; A61K33/24; (+6)**Publication** US6121244 (A) - 2000-09-19**Priority Date:** 1997-09-19**Info:****66 Injicerbare farmaceutiske formuleringer af partricinderivater****Inventor:** BRUZZESE TIBERIO [IT]; FERRARI VALERIO MARIA [MC]**Applicant:** PRO APARTS INVESTIMENTOS E CON [PT]**EC:****IPC:** A61K31/70; A61K47/24; A61K9/08; (+9)**Publication** DK1089710 (T3) - 2005-10-17**Priority Date:** 1998-06-25**Info:****67 FORME FARMACEUTICHE CONTENENTI CLODRONATI PER SOMMINISTRAZIONE INTRAMUSCOLARE AD ELEVATA TOLLERABILITA' LOCALE****Inventor:** MOZZI GIOVANNI; BONABELLO ANGELO (+1)**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]**EC:****IPC:** A61K; (IPC1-7); A61K**Publication** ITMI992356 (A1) - 2001-05-11**Priority Date:** 1999-11-11**Info:** IT1314220 (B1) - 2002-12-06**68 Purification of Particina****Inventor:** BRUZZESE TIBERIO; FERRARI**Applicant:** QUATEX NV [AN]**VALERIO MARIA [MC]****EC:****IPC:** C12P**Publication** ITMI20000497 (A1) - 2001-09-13**Priority Date:** 2000-03-13**Info:** IT1318386 (B1) - 2003-08-25**69 Composition, useful for treatment of disease of skeletal system e.g. osteoporosis, comprises clodronates and having neutral or mildly acidic pH****Inventor:** BRUZZESE TIBERIO; MOZZI GIOVANNI (+1)**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]**EC:****IPC:** A61K; (IPC1-7); A61K**Publication** ITMI20000584 (A1) - 2001-09-21**Priority Date:** 2000-03-21**Info:** IT1318413 (B1) - 2003-08-25**70 PREPARAZIONI PER L'USO INTRAMUSCOLARE DI BISFOSFONATI****Inventor:** MOZZI GIOVANNI; BONABELLO ANGELO (+1)**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]**EC:****IPC:** A61K; (IPC1-7); A61K**Publication** ITMI20001174 (A1) - 2001-11-26**Priority Date:** 2000-05-26**Info:** IT1318540 (B1) - 2003-08-27**71 Composition, useful for treatment of disease of skeletal system e.g. osteoporosis, comprises clodronates and having neutral or mildly acidic pH****Inventor:** MOZZI GIOVANNI; BONABELLO**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]**ANGELO****EC:****IPC:** A61K; (IPC1-7); A61K**Publication** ITMI20001694 (A1) - 2002-01-25**Priority Date:** 2000-07-25**Info:** IT1318638 (B1) - 2003-08-27**72 USO DELLA MEPARTRICINA PER IL TRATTAMENTO DELLE SINDRONI PROSTATICHE CRONICHE**

**Inventor:** BRUZZESE TIBERIO      **Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**EC:**      **IPC:** A61K  
**Publication** ITMI20002230 (A1) - 2002-04-16      **Priority Date:** 2000-10-16  
**Info:** IT1319218 (B1) - 2003-09-26

**73** **Injectable pharmaceutical formulations for partricin derivatives**

**Inventor:** BRUZZESE TIBERIO [IT]; FERRARI      **Applicant:** QUATEX NV [AN]  
VALERIO MARIA [MC]  
**EC:** A61K31/7048; A61K47/24; (+2)      **IPC:** A61K31/7048; A61K31/7056; A61K31/706;  
(+14)  
**Publication** US6586407 (B1) - 2003-07-01      **Priority Date:** 1998-06-25  
**Info:**

**74** **Pharmaceutical compositions containing clodronates for high local tolerance intramuscular administration**

**Inventor:** MOZZI GIOVANNI [IT]; BONABELLO      **Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
ANGELO [IT] (+1)  
**EC:** A61K31/663; A61K47/02; (+3)      **IPC:** A61K47/02; A61K47/10; A61K9/00; (+8)  
**Publication** EP1136069 (A1) - 2001-09-26      **Priority Date:** 2000-03-21  
**Info:**

**75** **USO DI FLUOROCHINOLONI CONTRO LE INFESZIONI DA MICOBATTERI**

**Inventor:** BRUZZESE TIBERIO      **Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**EC:**  
**Publication** ITMI20010330 (A1) - 2002-08-16      **Priority Date:** 2001-02-16  
**Info:**

Data supplied from the **espacenet** database — Worldwide

**RESULT LIST**

85 results found in the Worldwide database for:

Tiberio Brusse as the inventor

Sorting criteria: **Upload Date** Priority Date Inventor Applicant Ecla**76 COMPOSIZIONE PER L'ASSUNZIONE ORALE DI LICOPENE E VITAMINA D E SUO USO**

**Inventor:** BRUZZESE TIBERIO ; MOZZI GIOVANNI  
**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:**  
**Publication:** ITMI20010379 (A1) - 2002-08-23 **Priority Date:** 2001-02-23  
**Info:**

**77 Intramuscular pharmaceutical composition comprising dexibuprofen and uses thereof**

**Inventor:** BRUZZESE TIBERIO [IT] ; MOZZI GIOVANNI [IT] (+1)  
**Applicant:** PRODOTTI ANTIBIOTICI SPA [IT]  
**IPC:** A61K31/192; A61K31/20; A61K36/736; (+14)  
**Publication:** EP1175913 (A1) - 2002-01-30 **Priority Date:** 2000-07-28  
**Info:**

**BIPHOSPHONATE PHARMACEUTICAL FORMULATIONS****78 (WATER EMULSION OF LIPIDS/PHOSPHOLIPIDS) AND USE THEREOF**

**Inventor:** BRUZZESE TIBERIO [IT] **Applicant:** BRUZZESE TIBERIO [IT]  
**IPC:** A61K31/663; A61K47/14; A61K47/24; (+12)  
**Publication:** WO2005044280 (A1) - 2005-05-19 **Priority Date:** 2003-11-11  
**Info:**

**79 processo para preparação de uma composição compreendendo compostos insaturados**

**Inventor:** BRUZZESE TIBERIO **Applicant:** PRO APARTS INVESTIMENTOS E CON [PT]  
**IPC:** C11B3/10; C11B7/00; C11B3/00; (+3)  
**Publication:** BRPI0416742 (A) - 2007-01-16 **Priority Date:** 2003-11-19  
**Info:**

**80 USE OF PARTRICIN DERIVATIVES FOR TREATING FUNGAL AND PROTOZOAL INFECTIONS**

**Inventor:** BRUZZESE TIBERIO [IT] **Applicant:** BRUZZESE TIBERIO [IT]  
**IPC:** A61K31/35; A61K31/35; (IPC1-7); A61K31/35; (+1)  
**Publication:** WO2005053677 (A1) - 2005-06-16 **Priority Date:** 2003-11-24  
**Info:**

**81 Method for the production of wine and wine obtained from such method**

**Inventor:** VILLA ADALBERTO [CH] ; BELLACIOMA ATTILIO [IT] (+2)  
**Applicant:** SAINT SIMEON MARKETING E INVES [PT]  
**IPC:** C12G1/00; C12G1/02; C12G1/00  
**Publication:** EP1892286 (A1) - 2008-02-27 **Priority Date:** 2006-07-27  
**Info:**

**82 Method for the production of wine and wine obtained from such method**

**Inventor:** ADALBERTO VILLA ; CLAUDIO RIPONI (+2) **Applicant:** SAINT SIMEON MARKETING E INVES  
**IPC:** C12G  
**Publication:** ZA200706266 (A) - 2008-06-25 **Priority Date:** 2006-07-27  
**Info:**

**83 PROCESS FOR THE PREPARATION OF A COMPOSITION COMPRISING POLYUNSATURATED COMPOUNDS**

**Inventor:** BRUZZESE TIBERIO [IT] **Applicant:** PRO APARTS INVESTIMENTOS E CON [PT]  
**IPC:** C11B3/10; C11B7/00; (+2)  
**Publication:** HR20080415 (T3) - 2008-09-30 **Priority Date:** 2003-11-19  
**Info:**

**84 USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED N-3 FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES**

**Inventor:** BRUZZESE TIBERIO [IT] **Applicant:** BRUZZESE TIBERIO [IT]  
**IPC:** A61K31/202; A61P25/08; A61P25/18; (+3)  
**Publication:** PT1706106 (E) - 2009-09-04 **Priority Date:** 2004-01-21  
**Info:**

**85 COMPOSITION OF N-3 FATTY ACIDS HAVING HIGH CONCENTRATION OF EPA AND/OR DHA AND CONTAINING N-6 FATTY ACIDS**

**Inventor:** BRUZZESE TIBERIO [IT] **Applicant:**  
**IPC:** A61K31/20; A61K31/185  
**Publication:** US2010160435 (A1) - 2010-06-24 **Priority Date:** 2005-08-10  
**Info:**

Data supplied from the **espacenet** database — Worldwide